Ideal regimen for induction chemotherapy in nasopharyngeal cancer: Still a hot issue?

Radiother Oncol. 2022 Dec:177:111-112. doi: 10.1016/j.radonc.2022.10.033. Epub 2022 Nov 3.

Authors

Francesca De Felice¹, Alessio Cirillo², Andrea Botticelli²

Affiliations

¹ Radiation Oncology, Policlinico Umberto I, Department of Radiological, Oncological and Pathological Sciences, "Sapienza" University of Rome, Viale Regina Elena 326, 00161 Rome, Italy. Electronic address: [email protected].
² Medical Oncology Unit B, Policlinico Umberto I, Department of Radiological, Oncological and Pathological Sciences, "Sapienza" University of Rome, Viale Regina Elena 326, 00161 Rome, Italy.

PMID: 36336112
DOI: 10.1016/j.radonc.2022.10.033

No abstract available

Keywords: Cisplatin; Gemcitabine; Induction chemotherapy; Nasopharynx; Radiotherapy; Taxane.

Publication types

Editorial

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Cisplatin / therapeutic use
Deoxycytidine / therapeutic use
Fluorouracil
Humans
Induction Chemotherapy
Nasopharyngeal Carcinoma / drug therapy
Nasopharyngeal Neoplasms* / drug therapy
Nasopharyngeal Neoplasms* / radiotherapy

Substances

Deoxycytidine
Cisplatin
Fluorouracil